Literature DB >> 11744616

Combined three-dimensional quantitative structure-activity relationship analysis of cytochrome P450 2B6 substrates and protein homology modeling.

Qinmi Wang1, James R Halpert.   

Abstract

Understanding the basis of the substrate specificity of cytochrome P450 2B6 (CYP2B6) is important for determining the role of this enzyme in drug metabolism and for predicting new substrates. Pharmacophores were generated for 16 structurally diverse CYP2B6 substrates with Catalyst after overlapping the reaction sites. Two pharmacophores were determined for the CYP2B6 binding site. Both include two hydrophobes and one hydrogen bond acceptor. The three-dimensional structure of CYP2B6 was then modeled based on the crystal structure of CYP2C5. Benzyloxyresorufin and 7-ethoxy-4-trifluoromethylcoumarin, the two lowest K(m) substrates in the training set, were then docked in the active site of CYP2B6. The pharmacophores were combined with the CYP2B6 model by comparing the docking results and the mapping of the two substrates with the pharmacophores. The results indicated that the active site of CYP2B6 complements the pharmacophores. The pharmacophores and the CYP2B6 model were used in conjunction to predict the K(m) values of substrates in a test set of five compounds and yielded satisfactory predictions for benzphetamine, cinnarizine, bupropion, and verapamil but not lidocaine. The CYP2B6 model, the pharmacophores, and the combination of the model with these pharmacophores provide insight into the interactions of CYP2B6 with substrates. The pharmacophores may be used as queries to search a database to predict new substrates for CYP2B6 when the reaction site is known (N- or O-dealkylation). For C-hydroxylation, the CYP2B6 model is helpful in evaluating the possible reaction sites in order for the pharmacophores to predict corresponding K(m) values.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11744616     DOI: 10.1124/dmd.30.1.86

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  12 in total

1.  High-throughput screening assays for CYP2B6 metabolism and inhibition using fluorogenic vivid substrates.

Authors:  Bryan D Marks; Tony A Goossens; Heidi A Braun; Mary S Ozers; Ronald W Smith; Connie Lebakken; Olga V Trubetskoy
Journal:  AAPS PharmSci       Date:  2003

2.  Evaluation of descriptors and classification schemes to predict cytochrome substrates in terms of chemical information.

Authors:  John H Block; Douglas R Henry
Journal:  J Comput Aided Mol Des       Date:  2008-01-23       Impact factor: 3.686

3.  Atomic level characterization of the nonproton ligand-sensing domain of ASIC3 channels.

Authors:  Ye Yu; Wei-Guang Li; Zhi Chen; Hui Cao; Huaiyu Yang; Hualiang Jiang; Tian-Le Xu
Journal:  J Biol Chem       Date:  2011-05-17       Impact factor: 5.157

Review 4.  Emerging approaches to probing ion channel structure and function.

Authors:  Wei-Guang Li; Tian-Le Xu
Journal:  Neurosci Bull       Date:  2012-08       Impact factor: 5.203

5.  Roles of Residues F206 and V367 in Human CYP2B6: Effects of Mutations on Androgen Hydroxylation, Mechanism-Based Inactivation, and Reversible Inhibition.

Authors:  Hsia-Lien Lin; Haoming Zhang; Cesar Kenaan; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2016-08-18       Impact factor: 3.922

6.  Single Heteroatom Substitutions in the Efavirenz Oxazinone Ring Impact Metabolism by CYP2B6.

Authors:  Philip M Cox; Namandjé N Bumpus
Journal:  ChemMedChem       Date:  2016-11-10       Impact factor: 3.466

7.  Structure and function of cytochromes P450 2B: from mechanism-based inactivators to X-ray crystal structures and back.

Authors:  James R Halpert
Journal:  Drug Metab Dispos       Date:  2011-04-18       Impact factor: 3.922

Review 8.  Molecular characterization of CYP2B6 substrates.

Authors:  Sean Ekins; Manisha Iyer; Matthew D Krasowski; Evan D Kharasch
Journal:  Curr Drug Metab       Date:  2008-06       Impact factor: 3.731

9.  Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-A resolution.

Authors:  Sean C Gay; Manish B Shah; Jyothi C Talakad; Keiko Maekawa; Arthur G Roberts; P Ross Wilderman; Ling Sun; Jane Y Yang; Stephanie C Huelga; Wen-Xu Hong; Qinghai Zhang; C David Stout; James R Halpert
Journal:  Mol Pharmacol       Date:  2010-01-08       Impact factor: 4.436

10.  Single mutations change CYP2F3 from a dehydrogenase of 3-methylindole to an oxygenase.

Authors:  Jaya S Kartha; Konstantine W Skordos; Hao Sun; Clifton Hall; LaHoma M Easterwood; Christopher A Reilly; Eric F Johnson; Garold S Yost
Journal:  Biochemistry       Date:  2008-08-22       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.